EPISODE · Nov 10, 2021 · 33 MIN
Theranostics and Neuroendocrine Tumours: Where do we go next?
from The Oncology Podcast · host Oncology News Australia
Send us Fan MailThe Oncology Podcast - Delivering Oncology News DifferentlyWelcome to episode 6 in ourExperts On Point podcast series brought to you from The Oncology Podcast.Today's podcast explores the role of theranostics in neuroendocrine tumours - in celebration of World NET Cancer Day on the 10th November 2021.Rachael Babin chats to Simone Leydon and Aviral Singh about the future of theranostics in Australia.Simone Leyden is CEO, and Co-Founder of NeuroEndocrine Cancer Australia. Dr Aviral Singh who is a Specialist Nuclear Medicine Physician from Germany and Clinical Research and Development Manager for GenesisCare. He practices Theranostics for the management of Neuroendocrine Neoplasms and Prostate Cancer.We hope you enjoy today's episode.For news and podcast updates subscribe to the The Oncology Newsletter, a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK
Embed this episode
What this episode covers
Send us Fan Mail The Oncology Podcast - Delivering Oncology News Differently Welcome to episode 6 in ourExperts On Point podcast series brought to you from The Oncology Podcast. Today's podcast explores the role of theranostics in neuroendocrine tumours - in celebration of World NET Cancer Day on the 10th November 2021. Rachael Babin chats to Simone Leydon and Aviral Singh about the future of theranostics in Australia. Simone Leyden is CEO, and Co-Founder of NeuroEndocrine Cancer Australia...
NOW PLAYING
Theranostics and Neuroendocrine Tumours: Where do we go next?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.